Patents Assigned to MINERVA NEUROSCIENCES, INC.
-
Patent number: 11766430Abstract: The present disclosure relates to methods of treating pain, fibromyalgia, neuropathy, chemotherapy-induced pain, promoting an antihyperalgesic effect, and reducing sensitivity to pain, in a subject in need of such treatment comprising the administration of a therapeutically effective amount of Compound I, or a pharmaceutically acceptable salt, solvate, or prodrug thereof.Type: GrantFiled: September 4, 2019Date of Patent: September 26, 2023Assignee: Minerva Neurosciences, Inc.Inventors: Remy Luthringer, Nadine Noel, Jay Saoud
-
Patent number: 11464744Abstract: This disclosure relates to gastro-resistant, controlled release dosage forms comprising Compound (I): or a pharmaceutically acceptable salt and/or solvate thereof, the pharmacokinetic properties of these dosage forms, and the preparation of the same. The novel dosage forms disclosed herein are useful in reducing the risk of QT prolongation in a subject and in treating a disorder in a subject in need thereof, e.g., a subject diagnosed with schizophrenia, for example, in treating the negative symptoms in a subject diagnosed with schizophrenia having the CYP2D6 EM genotype.Type: GrantFiled: June 21, 2018Date of Patent: October 11, 2022Assignee: Minerva Neurosciences, Inc.Inventors: Jay Saoud, Remy Luthringer, Sandra Werner, Nadine Noel, Emmanuelle Georgi
-
Patent number: 11083723Abstract: The present application relates to the use of roluperidone, i.e., Compound (I): and salts, solvates, pharmaceutical compositions, and dosage forms thereof, for use in methods of treating negative symptoms and disorders (e.g., autism disorders, amblyopia, personality disorders, traumatic brain injury), as well as increasing neuroplasticity and promoting neuroprotection in subjects in need thereof.Type: GrantFiled: August 21, 2019Date of Patent: August 10, 2021Assignee: Minerva Neurosciences, Inc.Inventor: Remy Henri Luthringer
-
Patent number: 10799493Abstract: The disclosure provides a novel polymorph of Compound (I): 2-((1-(2-(4-Fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one monohydrochloride dihydrate, i.e., Form (A) of Compound (I).HCl.2H2O. Pharmaceutical compositions comprising Form (A) of Compound (I).HCl.2H2O and related methods of treatment are also disclosed.Type: GrantFiled: March 1, 2019Date of Patent: October 13, 2020Assignee: Minerva Neurosciences, Inc.Inventors: Remy Luthringer, Nadine Noel, Sandra Werner
-
Publication number: 20200223838Abstract: Disclosed herein are compositions and methods for treating depression using compositions comprising a compound of formula I. Disclosed herein are compositions and methods for treating depression using compositions comprising phenoxypropylamine compounds and derivatives having selective affinity for and antagonistic activity against the 5-HT1A receptor, as well as 5-HT reuptake inhibitory activity. In addition, compositions and methods for treating depression using compositions comprising a compound of formula II are disclosed. Methods of treating or diminishing at least one symptom of depression in a human subject with a composition comprising a compound of the formula (I) or formula (II), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, are also disclosed.Type: ApplicationFiled: March 25, 2020Publication date: July 16, 2020Applicant: Minerva Neurosciences, Inc.Inventors: Lorenzo PELLEGRINI, Argeris KARABELAS, Remy LUTHRINGER
-
Patent number: 10258614Abstract: The disclosure provides a novel polymorph of Compound (I): 2-((1-(2-(4-Fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one monohydrochloride dihydrate, i.e., Form (A) of Compound (I).HCl.2H2O. Pharmaceutical compositions comprising Form (A) of Compound (I).HCl.2H2O and related methods of treatment are also disclosed.Type: GrantFiled: July 17, 2017Date of Patent: April 16, 2019Assignee: Minerva Neurosciences, Inc.Inventors: Remy Luthringer, Nadine Noel, Sandra Werner
-
Patent number: 9732059Abstract: Disclosed herein are compositions and methods for treating schizophrenia and symptoms of schizophrenia, including negative symptoms of schizophrenia.Type: GrantFiled: July 20, 2011Date of Patent: August 15, 2017Assignee: Minerva Neurosciences, Inc.Inventors: Remy Henri Luthringer, Lorenzo Pellegrini, Argeris N. Karabelas
-
Patent number: 9730920Abstract: The disclosure provides a novel polymorph of Compound (I): 2-((1-(2-(4-Fluorophenyl)-2-oxoethyl)piperidin-4-yl) methyl)isoindolin-1-one monohydrochloride dihydrate, i.e., Form (A) of Compound (I)•HC1•2H2O. Pharmaceutical compositions comprising Form (A) of Compound (I)•HC1•2H2O and related methods of treatment are also disclosed.Type: GrantFiled: September 28, 2016Date of Patent: August 15, 2017Assignee: Minerva Neurosciences, Inc.Inventors: Remy Luthringer, Nadine Noel, Sandra Werner
-
Patent number: 9458130Abstract: The disclosure provides a novel polymorph of Compound (I): 2-((1-(2-(4-Fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one monohydrochloride dihydrate, i.e., Form (A) of Compound (I).HCl.2H2O. Pharmaceutical compositions comprising Form (A) of Compound (I).HCl.2H2O and related methods of treatment are also disclosed.Type: GrantFiled: November 30, 2015Date of Patent: October 4, 2016Assignee: Minerva Neurosciences, Inc.Inventor: Remy Luthringer
-
Publication number: 20140206722Abstract: Disclosed herein are compositions and methods for treating depression using compositions comprising a compound of formula I. Disclosed herein are compositions and methods for treating depression using compositions comprising phenoxypropylamine compounds and derivatives having selective affinity for and antagonistic activity against the 5-HT1A receptor, as well as 5-HT reuptake inhibitory activity. In addition, compositions and methods for treating depression using compositions comprising a compound of formula II are disclosed. Methods of treating or diminishing at least one symptom of depression in a human subject with a composition comprising a compound of the formula (I) or formula (II), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, are also disclosed.Type: ApplicationFiled: January 24, 2014Publication date: July 24, 2014Applicant: MINERVA NEUROSCIENCES, INC.Inventors: Lorenzo Pellegrini, Argeris Karabelas, Remy Luthringer